Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to $41.6 million.

  • Angiodynamics' Cash & Equivalents fell 2301.95% to $41.6 million in Q4 2025 from the same period last year, while for Nov 2025 it was $41.6 million, marking a year-over-year decrease of 2301.95%. This contributed to the annual value of $55.9 million for FY2025, which is 2651.07% down from last year.
  • Latest data reveals that Angiodynamics reported Cash & Equivalents of $41.6 million as of Q4 2025, which was down 2301.95% from $38.8 million recorded in Q3 2025.
  • In the past 5 years, Angiodynamics' Cash & Equivalents registered a high of $78.5 million during Q1 2024, and its lowest value of $23.9 million during Q1 2022.
  • Over the past 5 years, Angiodynamics' median Cash & Equivalents value was $44.7 million (recorded in 2023), while the average stood at $45.9 million.
  • Per our database at Business Quant, Angiodynamics' Cash & Equivalents tumbled by 5614.02% in 2022 and then surged by 16053.93% in 2024.
  • Quarter analysis of 5 years shows Angiodynamics' Cash & Equivalents stood at $34.3 million in 2021, then fell by 12.93% to $29.9 million in 2022, then soared by 103.96% to $60.9 million in 2023, then fell by 11.18% to $54.1 million in 2024, then fell by 23.02% to $41.6 million in 2025.
  • Its Cash & Equivalents stands at $41.6 million for Q4 2025, versus $38.8 million for Q3 2025 and $55.9 million for Q2 2025.